Bulgaria
· Delayed Price · Currency is BGN Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of BGN 442.52 million. The enterprise value is 968.94 million.
| Market Cap | 442.52M |
| Enterprise Value | 968.94M |
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | Jul 10, 2025 |
Share Statistics
Sopharma AD has 166.36 million shares outstanding. The number of shares has increased by 24.34% in one year.
| Current Share Class | 166.36M |
| Shares Outstanding | 166.36M |
| Shares Change (YoY) | +24.34% |
| Shares Change (QoQ) | +4.12% |
| Owned by Insiders (%) | 30.54% |
| Owned by Institutions (%) | 1.67% |
| Float | 115.15M |
Valuation Ratios
The trailing PE ratio is 15.80.
| PE Ratio | 15.80 |
| Forward PE | n/a |
| PS Ratio | 0.19 |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | 2.62 |
| P/OCF Ratio | 2.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.62, with an EV/FCF ratio of 5.75.
| EV / Earnings | 10.95 |
| EV / Sales | 0.43 |
| EV / EBITDA | 5.62 |
| EV / EBIT | 8.19 |
| EV / FCF | 5.75 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.24 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 3.93 |
| Debt / FCF | 3.26 |
| Interest Coverage | 5.89 |
Financial Efficiency
Return on equity (ROE) is 11.17% and return on invested capital (ROIC) is 4.07%.
| Return on Equity (ROE) | 11.17% |
| Return on Assets (ROA) | 3.01% |
| Return on Invested Capital (ROIC) | 4.07% |
| Return on Capital Employed (ROCE) | 7.45% |
| Revenue Per Employee | 372,204 |
| Profits Per Employee | 14,505 |
| Employee Count | 5,599 |
| Asset Turnover | 1.27 |
| Inventory Turnover | 4.30 |
Taxes
In the past 12 months, Sopharma AD has paid 11.93 million in taxes.
| Income Tax | 11.93M |
| Effective Tax Rate | 11.16% |
Stock Price Statistics
The stock price has increased by +32.65% in the last 52 weeks. The beta is -0.20, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | -0.20 |
| 52-Week Price Change | +32.65% |
| 50-Day Moving Average | 2.23 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 84.35 |
| Average Volume (20 Days) | 656,496 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of BGN 2.27 billion and earned 88.47 million in profits. Earnings per share was 0.17.
| Revenue | 2.27B |
| Gross Profit | 498.55M |
| Operating Income | 85.72M |
| Pretax Income | 106.88M |
| Net Income | 88.47M |
| EBITDA | 123.46M |
| EBIT | 85.72M |
| Earnings Per Share (EPS) | 0.17 |
Balance Sheet
The company has 52.11 million in cash and 549.67 million in debt, giving a net cash position of -497.56 million or -2.99 per share.
| Cash & Cash Equivalents | 52.11M |
| Total Debt | 549.67M |
| Net Cash | -497.56M |
| Net Cash Per Share | -2.99 |
| Equity (Book Value) | 887.50M |
| Book Value Per Share | 5.16 |
| Working Capital | 188.13M |
Cash Flow
In the last 12 months, operating cash flow was 203.20 million and capital expenditures -34.61 million, giving a free cash flow of 168.59 million.
| Operating Cash Flow | 203.20M |
| Capital Expenditures | -34.61M |
| Free Cash Flow | 168.59M |
| FCF Per Share | 1.01 |
Margins
Gross margin is 21.96%, with operating and profit margins of 3.78% and 3.90%.
| Gross Margin | 21.96% |
| Operating Margin | 3.78% |
| Pretax Margin | 4.71% |
| Profit Margin | 3.90% |
| EBITDA Margin | 5.44% |
| EBIT Margin | 3.78% |
| FCF Margin | 7.43% |
Dividends & Yields
This stock pays an annual dividend of 0.15, which amounts to a dividend yield of 5.64%.
| Dividend Per Share | 0.15 |
| Dividend Yield | 5.64% |
| Dividend Growth (YoY) | -68.18% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 190.42% |
| Buyback Yield | -24.34% |
| Shareholder Yield | -18.57% |
| Earnings Yield | 19.99% |
| FCF Yield | 38.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 2.13 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.13 |
| Piotroski F-Score | 4 |